A next-generation meningococcal serogroup b vaccine with improved effectiveness for all age groups
Ended Project Grant Awarded Last action
- Award ID
- R44AI124759
- Recipient
-
Omvax, Inc. UEI MKQKRT751Q19
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $6,000,000
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Funding
-
- $5,000,000.00 Federal
- $1,000,000.00 Non-federal
- Place of performance
- San Francisco, CA 94158, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $1,000,000 | $0 | |
| Amendment | $1,000,000 | $0 | |
| Amendment | $1,000,000 | $0 | |
| Amendment | $1,000,000 | $1,000,000 | |
| Original award | $1,000,000 | $0 |
Quick answers
Who received award R44AI124759?
R44AI124759 was awarded to Omvax, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 8, 2016.
How much is award R44AI124759 worth?
$6,000,000 has been obligated on R44AI124759: $5,000,000 in federal funding and $1,000,000 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award